SG10201805706XA - Immunoglobulin-like molecules directed against fibronectin-eda - Google Patents

Immunoglobulin-like molecules directed against fibronectin-eda

Info

Publication number
SG10201805706XA
SG10201805706XA SG10201805706XA SG10201805706XA SG10201805706XA SG 10201805706X A SG10201805706X A SG 10201805706XA SG 10201805706X A SG10201805706X A SG 10201805706XA SG 10201805706X A SG10201805706X A SG 10201805706XA SG 10201805706X A SG10201805706X A SG 10201805706XA
Authority
SG
Singapore
Prior art keywords
immunoglobulin
molecules
eda
directed against
molecules directed
Prior art date
Application number
SG10201805706XA
Other languages
English (en)
Inventor
Fatih Arslan
Original Assignee
Umc Utrecht Holding Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Umc Utrecht Holding Bv filed Critical Umc Utrecht Holding Bv
Publication of SG10201805706XA publication Critical patent/SG10201805706XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG10201805706XA 2013-12-12 2014-12-12 Immunoglobulin-like molecules directed against fibronectin-eda SG10201805706XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL2011944 2013-12-12
NL2011943 2013-12-12

Publications (1)

Publication Number Publication Date
SG10201805706XA true SG10201805706XA (en) 2018-08-30

Family

ID=52392177

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201604748YA SG11201604748YA (en) 2013-12-12 2014-12-12 Immunoglobulin-like molecules directed against fibronectin-eda
SG10201805706XA SG10201805706XA (en) 2013-12-12 2014-12-12 Immunoglobulin-like molecules directed against fibronectin-eda

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201604748YA SG11201604748YA (en) 2013-12-12 2014-12-12 Immunoglobulin-like molecules directed against fibronectin-eda

Country Status (14)

Country Link
US (2) US10011652B2 (fr)
EP (1) EP3080163B1 (fr)
JP (1) JP6698529B2 (fr)
KR (1) KR20160108322A (fr)
CN (1) CN106170496B (fr)
AU (1) AU2014360946B2 (fr)
BR (1) BR112016013641A2 (fr)
CA (1) CA2933471A1 (fr)
IL (1) IL246187A0 (fr)
MX (1) MX2016007691A (fr)
NZ (1) NZ721984A (fr)
SG (2) SG11201604748YA (fr)
WO (1) WO2015088348A1 (fr)
ZA (1) ZA201604048B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10011652B2 (en) 2013-12-12 2018-07-03 Umc Utrecht Holding B.V. Immunoglobulin-like molecules directed against fibronectin-EDA
WO2016093700A2 (fr) * 2014-12-12 2016-06-16 Umc Utrecht Holding B.V. Molécules de type immunoglobuline dirigées contre le domaine eda de la fibronectine
GB201507908D0 (en) 2015-05-08 2015-06-24 Philogen Spa IL2 and TNF immunoconjugates
CN108276491B (zh) * 2018-02-05 2021-01-12 南京薇熙生物医药科技有限公司 一种可特异性识别hpv18 l1蛋白的单克隆抗体及其应用
US20210095011A1 (en) 2018-05-03 2021-04-01 Encare Biotech B.V. Improved anti-fibronectin eda antibodies
CN111704653B (zh) * 2020-06-08 2023-10-03 深圳市图微安创科技开发有限公司 靶向于纤连蛋白衍生肽的抑制剂多肽化合物及其用途
DE202022100356U1 (de) 2022-01-22 2022-03-08 Fahad Ahmed Al Abbasi Ein System zur Analyse der Wirkung von Vitamin C bei stressinduzierten Herzfunktionsstörungen
WO2023170170A1 (fr) 2022-03-08 2023-09-14 Fundación Para La Investigación Médica Aplicada Nouvelles cellules de récepteur antigénique chimérique (car) et leurs utilisations médicales

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4980279A (en) 1986-04-15 1990-12-25 Scripps Clinic And Research Foundation Cellular fibronectin: polypeptides, anti-polypeptide antibodies and assay methods
US5843708A (en) 1988-01-05 1998-12-01 Ciba-Geigy Corporation Chimeric antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5108898A (en) * 1989-01-18 1992-04-28 Peters John H Use of fibronectin having a variable included type III repeat sequence as a marker for toxemia in pregnancy
US5420012A (en) 1989-05-08 1995-05-30 Locus Genex Oy Method for the detection of reactive conditions
WO1992017604A1 (fr) 1991-03-26 1992-10-15 Otsuka Pharmaceutical Factory, Inc. Anticorps monoclonal anti-eda
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5644033A (en) 1992-12-22 1997-07-01 Health Research, Inc. Monoclonal antibodies that define a unique antigen of human B cell antigen receptor complex and methods of using same for diagnosis and treatment
US20060024757A1 (en) * 2004-07-30 2006-02-02 Robert Hussa Detection of oncofetal fibronectin for selection of concepti
AU2005291486A1 (en) 2004-10-01 2006-04-13 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Novel antibodies directed to the mammalian EAG1 ion channel protein
RU2425054C2 (ru) * 2005-06-01 2011-07-27 Микромет Аг Антитела против il2
JP5221641B2 (ja) * 2007-04-02 2013-06-26 フィロゲン エスピーエー 腫瘍転移の血管新生と関連するフィブロネクチンのｅｄ−ａ抗原
US7824868B2 (en) * 2007-04-19 2010-11-02 Hoeoek Magnus Formation of superfibronectin by BBK32 and uses therefor
JP5204228B2 (ja) 2007-07-25 2013-06-05 フィロゲン エスピーエー 腫瘍転移の新生血管と関連するフィブリノーゲンのｅｄ−ａ抗原
US20130274448A1 (en) * 2010-10-26 2013-10-17 Umc Utrecht Holding B.V. Method for preventing myocardial infarction-related complications
US20130224236A1 (en) 2010-11-03 2013-08-29 University Of Washington Hsv-1 epitopes and methods for using same
US10011652B2 (en) 2013-12-12 2018-07-03 Umc Utrecht Holding B.V. Immunoglobulin-like molecules directed against fibronectin-EDA
WO2016093700A2 (fr) 2014-12-12 2016-06-16 Umc Utrecht Holding B.V. Molécules de type immunoglobuline dirigées contre le domaine eda de la fibronectine

Also Published As

Publication number Publication date
JP6698529B2 (ja) 2020-05-27
US10011652B2 (en) 2018-07-03
NZ721984A (en) 2020-01-31
KR20160108322A (ko) 2016-09-19
CA2933471A1 (fr) 2015-06-18
ZA201604048B (en) 2018-05-30
EP3080163A1 (fr) 2016-10-19
SG11201604748YA (en) 2016-07-28
WO2015088348A1 (fr) 2015-06-18
CN106170496B (zh) 2019-10-08
CN106170496A (zh) 2016-11-30
EP3080163B1 (fr) 2020-02-12
AU2014360946A1 (en) 2016-07-14
BR112016013641A2 (pt) 2017-08-08
AU2014360946B2 (en) 2020-06-25
US10723789B2 (en) 2020-07-28
MX2016007691A (es) 2017-05-01
JP2017506061A (ja) 2017-03-02
US20160368974A1 (en) 2016-12-22
US20180346557A1 (en) 2018-12-06
IL246187A0 (en) 2016-07-31

Similar Documents

Publication Publication Date Title
SG10201805706XA (en) Immunoglobulin-like molecules directed against fibronectin-eda
PH12019500694A1 (en) Factor viii compositions and methods of making and using the same
MX2020001198A (es) Agentes de union que se unen a ligando 1 de muerte programada (pd-l1) y grupo de diferenciacion 137 (cd137) y uso de los mismos.
SG10201906859PA (en) Novel proteins specific for angiogenesis
MX2018009524A (es) Composiciones del polipeptido de fusion tnfr: fc exentas de arginina y metodos de uso.
WO2017024317A3 (fr) Procédés pour induire la dégradation de protéine ciblée par des molécules bifonctionnelles
MX2017014125A (es) Variantes de alfa-amilasa y polinucleotidos que codifican las mismas.
MX2016002571A (es) Regulador de ph de transduccion.
PH12014501912A1 (en) Cx3cr1-binding polypeptides
MX2021008318A (es) Nuevos polipeptidos de union especifica y usos de los mismos.
MX362632B (es) Proteínas de dominio de armazón basadas en fibronectina que se unen a la proteína convertasa subtilisina kexina tipo q (pcsk9).
WO2014076321A8 (fr) Nouveaux polypeptides de liaison spécifique et leurs utilisations
MX2016001601A (es) Separacion de anticuerpos biespecificos y subproductos de produccion de anticuerpos biespecificos utilizando cromatografia de hidroxiapatita.
EP3321360A3 (fr) Variants d'alpha-amylase et polynucléotides les codant
IN2014DN06164A (fr)
WO2015110473A3 (fr) Variants de pullulanase et polynucléotides les codant
MX2015000754A (es) Proteinas de btnl3, acidos nucleicos, y anticuerpos y los usos de los mismos.
EP3964575A3 (fr) Variants d'alpha-amylase et polynucléotides codant pour ces derniers
WO2014195356A3 (fr) Variants d'alpha-amylase et polynucléotides les codant
WO2013163590A3 (fr) Variants du polypeptide gh61 et polynucléotides codant pour ceux-ci
WO2016044436A3 (fr) Anticorps anti-vasa et leurs procédés de production et d'utilisation
MX2017007663A (es) Moleculas tipo inmunoglobulina dirigidas contra fibronectina eda.
MX367767B (es) Polipéptidos que tienen actividad alfa-xilosidasa y polinucleótidos que los codifican.
BR112015019719A2 (pt) Proteínas melhoradas de ligação ao tnf
WO2016138167A3 (fr) Variants de cellobiohydrolase et polynucléotides codant pour ces derniers